Year None2022202120202019201820172016 Date Latest Press Release August 4, 2022 Eiger BioPharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update July 28, 2022 Eiger BioPharmaceuticals to Host Conference Call for Second Quarter 2022 Financial Results and Business Update on Thursday, August 4 July 20, 2022 Eiger Receives European Approval for Zokinvy® (lonafarnib) for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies July 18, 2022 Eiger Appoints Senior Human Resources and Organizational Executive Lisa Kelly-Croswell to Board of Directors June 27, 2022 Eiger BioPharmaceuticals Announces Results from Multiple Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022 June 13, 2022 Eiger BioPharmaceuticals Announces New Data Supporting Broader Potential of Avexitide in Patients with Post-Bariatric Hypoglycemia and Hyperinsulinemic Hypoglycemia After Gastrointestinal Surgeries June 8, 2022 Eiger BioPharmaceuticals Announces Multiple Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022 June 7, 2022 Eiger BioPharmaceuticals Enters into $75M Term Loan Agreement and $5M Stock Purchase Agreement with Innovatus Capital Partners to Refinance Existing Debt Facility and Further Strengthen Cash Position Ahead of Key Milestones June 3, 2022 Eiger BioPharmaceuticals to Present at the Jefferies Global Healthcare Conference May 20, 2022 Eiger Receives Positive CHMP Opinion for Zokinvy as a Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
